Chi KN

Oct 23, 2023 | gisweb.vwd.com | de Wit R |De J |Chi KN |Berry WR

* Phase III PSMAfore trial with Pluvicto(TM) met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.41(1); Pluvicto more than doubled median rPFS to 12.0 months per updated analysis*(1) * Pluvicto also showed improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints(1) * Overall survival (OS) data interpretation at second interim analysis was confounded by 84% crossover(1); PSMAfore...